These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 1972054)

  • 1. [Remoxipride, a selective antagonist of dopamine D2 receptors, in the treatment of delusional psychoses].
    Lewander T; Westerberg SE; Ogren SO; Von Bahr C; Köhler C
    Encephale; 1990; 16(2):153-7. PubMed ID: 1972054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early phase II clinical trial of remoxipride in treatment of schizophrenia with measurements of prolactin and neuroleptic activity.
    Chouinard G
    J Clin Psychopharmacol; 1987 Jun; 7(3):159-64. PubMed ID: 2885345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind comparative multicentre study of controlled-release remoxipride, immediate-release remoxipride and haloperidol in schizophrenia.
    Hebenstreit GF; Laux G; Schubert H; Beckmann H; Amman J; Bunse J; Eikmeier G; Geretsegger C; Kanitz RD; Kanzow WT
    Pharmacopsychiatry; 1991 Sep; 24(5):153-8. PubMed ID: 1685572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atypical neuroleptics in acute schizophrenia: a double-blind comparative study of remoxipride and haloperidol.
    den Boer JA; Westenberg HG
    Psychopharmacol Bull; 1990; 26(1):99-107. PubMed ID: 1973547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Selective antidopaminergic properties of remoxiprid, a new potential antipsychotic agent].
    Ogren SO; Hall H; Köhler C; Magnusson O; Florvall L
    Arzneimittelforschung; 1985; 35(8):1227-31. PubMed ID: 2866774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open multicentre study of the treatment of florid schizophrenia with remoxipride.
    McCreadie RG; Morrison D; Eccleston D; Gall RG; Loudon J; Mitchell MJ
    Acta Psychiatr Scand; 1985 Aug; 72(2):139-43. PubMed ID: 2864790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel pharmacological approaches to the treatment of schizophrenia.
    Fink-Jensen A
    Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remoxipride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in schizophrenia.
    Wadworth AN; Heel RC
    Drugs; 1990 Dec; 40(6):863-79. PubMed ID: 1981869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of remoxipride controlled release and immediate release capsules in schizophrenic patients.
    Widerlöv E; Franzén G; Jansson P; Movin G
    Int Clin Psychopharmacol; 1990 Apr; 5(2):125-34. PubMed ID: 1974271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remoxipride in schizophrenia: effects on plasma prolactin.
    Chouinard G; Turnier L; Kallai-Sanfacon MA
    Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(5-6):599-603. PubMed ID: 2868493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double blind comparative study of remoxipride and haloperidol in acute schizophrenic patients.
    Den Boer JA; Ravelli DP; Huisman J; Ohrvik J; Verhoeven WM; Westenberg HG
    Psychopharmacology (Berl); 1990; 102(1):76-84. PubMed ID: 1975448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An early phase II clinical trial of remoxipride in schizophrenia with measurement of plasma neuroleptic activity.
    Chouinard G; Turnier L
    Psychopharmacol Bull; 1986; 22(1):267-71. PubMed ID: 2873615
    [No Abstract]   [Full Text] [Related]  

  • 14. Antipsychotic effect of remoxipride, a new substituted benzamide with selective antidopaminergic activity.
    Lund Laursen A; Gerlach J
    Acta Psychiatr Scand; 1986 Jan; 73(1):17-21. PubMed ID: 2938421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remoxipride in schizophrenia. A preliminary report.
    den Boer JA; Verhoeven WM; Westenberg HG
    Acta Psychiatr Scand; 1986 Oct; 74(4):409-14. PubMed ID: 2880457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open study of remoxipride, a benzamide derivative, in schizophrenia.
    Lindström L; Besev G; Stening G; Widerlöv E
    Psychopharmacology (Berl); 1985; 86(1-2):241-3. PubMed ID: 2862658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life and response of negative symptoms in schizophrenia to haloperidol and the atypical antipsychotic remoxipride. The Canadian Remoxipride Group.
    Awad AG; Lapierre YD; Angus C; Rylander A
    J Psychiatry Neurosci; 1997 Jul; 22(4):244-8. PubMed ID: 9262046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A dose-finding study with remoxipride in the acute treatment of schizophrenic patients.
    Lapierre YD; Ancill R; Awad G; Bakish D; Beaudry P; Bloom D; Chandrasena R; Das M; Durand C; Elliott D
    J Psychiatry Neurosci; 1992 Oct; 17(4):134-45. PubMed ID: 1450186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Atypical neuroleptics. Review of the available clinical data].
    Verhoeven WM; Den Boer JA
    Encephale; 1990; 16(6):439-44. PubMed ID: 1983216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remoxipride and haloperidol in the acute phase of schizophrenia: a double-blind comparison.
    Deo R; Soni S; Rastogi SC; Levine S; Plant I; Edwards JG; Mitchell M; Chanas A
    Acta Psychiatr Scand Suppl; 1990; 358():120-4. PubMed ID: 1978470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.